| Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer (NCT02245100) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2014-07-22 |
| Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (NCT02035527) | Ohio State University Comprehensive Cancer Center | 2014-04-14 |
| Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy (NCT01728480) | Roswell Park Cancer Institute | 2014-01-01 |
| Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiation Therapy (NCT01674374) | Roswell Park Cancer Institute | 2013-05-01 |
| PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (NCT01816984) | University of Chicago | 2013-05-01 |
| Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer (NCT01528137) | Stanford University | 2012-05-01 |
| TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck (NCT01334177) | University of Washington | 2011-06-01 |
| Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab (NCT00939627) | National Cancer Institute (NCI) | 2009-07-01 |
| Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer (NCT01637194) | Fox Chase Cancer Center | 2008-11-01 |
| Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (NCT00513435) | National Cancer Institute (NCI) | 2007-07-01 |
| Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (NCT00507767) | National Cancer Institute (NCI) | 2007-07-01 |
| Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (NCT00103259) | National Cancer Institute (NCI) | 2005-07-01 |
| Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer (NCT00114283) | National Cancer Institute (NCI) | 2005-03-01 |
| SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (NCT00095628) | National Cancer Institute (NCI) | 2005-01-01 |
| S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (NCT00096512) | National Cancer Institute (NCI) | 2004-10-01 |
| Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer (NCT00068497) | National Cancer Institute (NCI) | 2003-08-01 |
| Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck (NCT00033618) | National Cancer Institute (NCI) | 2002-11-01 |